卒中：回眸2024

doi:10.3969/j.issn.1673-5765.2025.01.001

摘要/Abstract

摘要： 2024年，脑血管病临床研究进展显著。全球卒中领域研究者们共同的智慧和努力进一步完善了脑血管病的诊疗和管理策略。在出血性卒中领域，特别是在硬膜下血肿和原发性脑出血的治疗方面，研究取得了令人振奋的突破性进展。同时，缺血性卒中作为近年来的研究热点，在静脉溶栓、动脉取栓和二级预防等多个方面，不断涌现出更多高质量的研究成果，为临床诊疗提供了更多、更坚实的证据。本文将对2024年脑血管病领域的关键临床研究结果进行总结和解读，旨在帮助读者更好地把握当前的研究热点，深入理解其意义。

关键词: 脑血管病; 缺血性卒中; 出血性卒中; 再灌注; 取栓; 静脉溶栓; 二级预防

Abstract: In 2024, significant advancements were made in clinical research on cerebrovascular diseases. Stroke researchers worldwide have actively contributed their expertise, and further refined the diagnosis, treatment, and management strategies for cerebrovascular diseases. Exciting breakthroughs have been made in the field of hemorrhagic stroke, including the treatment of subdural hematoma and primary intracerebral hemorrhage. At the same time, as a research hotspot in recent years, ischemic stroke has seen a continuous emergence of high-quality research results in various aspects such as intravenous thrombolysis, arterial thrombectomy, and secondary prevention, providing more robust evidence for clinical diagnosis and treatment. This article aims to summarize and interpret the key clinical research findings in the field of cerebrovascular diseases in 2024, providing readers with a better understanding of the current research hotspots and deeply understand their significance.

Key words: Cerebrovascular disease; Ischemic stroke; Hemorrhagic stroke; Reperfusion; Thrombectomy; Intravenous thrombolysis; Secondary prevention

中图分类号:

熊云云, 李光硕, 马宇洁, 李祉馨, 沈柯佳, 马瑛, 孙大鹏, 孙溢阳, 王拥军. 卒中：回眸2024[J]. 中国卒中杂志, 2025, 20(1): 1-19.

XIONG Yunyun, LI Guangshuo, MA Yujie, LI Zhixin, SHEN Kejia, MA Ying, SUN Dapeng, SUN Yiyang, WANG Yongjun. Highlights in Stroke in 2024[J]. Chinese Journal of Stroke, 2025, 20(1): 1-19.

参考文献

[1] Van De WERF F，ADGEY J，ARDISSINO D，et al. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction：the ASSENT-2 double-blind randomised trial[J]. Lancet，1999，354（9180）：716-722.
[2] MENON B K，BUCK B H，SINGH N，et al. Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada（AcT）：a pragmatic，multicentre，open-label，registry-linked，randomised，controlled，non-inferiority trial[J]. Lancet，2022，400（10347）：161-169.
[3] WANG Y J，LI S Y，PAN Y S，et al. Tenecteplase versus alteplase in acute ischaemic cerebrovascular events（TRACE-2）：a phase 3，multicentre，open-label，randomised controlled，non-inferiority trial[J]. Lancet，2023，401（10377）：645-654.
[4] MENG X，LI S Y，DAI H G，et al. Tenecteplase vs. alteplase for patients with acute ischemic stroke：the ORIGINAL randomized clinical trial[J]. JAMA，2024，332（17）：1437-1445.
[5] PARSONS M W，YOGENDRAKUMAR V，CHURILOV L，et al. Tenecteplase versus alteplase for thrombolysis in patients selected by use of perfusion imaging within 4.5 h of onset of ischaemic stroke（TASTE）：a multicentre，randomised，controlled，phase 3 non-inferiority trial[J]. Lancet Neurol，2024，23（8）：775-786.
[6] MUIR K W，FORD G A，FORD I，et al. Tenecteplase versus alteplase for acute stroke within 4.5 h of onset（ATTEST-2）：a randomised，parallel group，open-label trial[J]. Lancet Neurol，2024，23（11）：1087-1096.
[7] TONG D，REEVES M J，HERNANDEZ A F，et al. Times from symptom onset to hospital arrival in the get with the guidelines—stroke program 2002 to 2009：temporal trends and implications[J]. Stroke，2012，43（7）：1912-1917.
[8] NOGUEIRA R G，JADHAV A P，HAUSSEN D C，et al. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct[J]. N Engl J Med，2018，378（1）：11-21.
[9] ALBERS G W，MARKS M P，KEMP S，et al. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging[J]. N Engl J Med，2018，378（8）：708-718.
[10] MA H，CAMPBELL B C V，PARSONS M W，et al. Thrombolysis guided by perfusion imaging up to 9 hours after onset of strok[J]. N Engl J Med，2019，380（19）：1795-1803.
[11] ALBERS G W，JUMAA M，PURDON B，et al. Tenecteplase for stroke at 4.5 to 24 hours with perfusion-imaging selection[J]. N Engl J Med，2024，390（8）：701-711.
[12] LEIFER D. Tenecteplase for stroke-opening the window？[J]. N Engl J Med，2024，390（8）：760-761.
[13] GOYAL M，BOSSHART S L，OSPEL J M. Tenecteplase for stroke at 4.5 to 24 hours[J/OL]. N Engl J Med，2024，390（18）：1729[2024-12-18]. https://doi.org/10.1056/NEJMc2403602.
[14] ASIF K S，OTITE F O，DESAI S M，et al. Mechanical thrombectomy global access for stroke（MT-GLASS）：a mission thrombectomy（MT-2020 Plus）study[J]. Circulation，2023，147（16）：1208-1220.
[15] Chinese Stroke Association. CSA declaration of next-generation reperfusion therapy for ischaemic stroke[J]. Stroke Vasc Neurol，2024，9（5）：459-460.
[16] XIONG Y Y，CAMPBELL B C V，SCHWAMM L H，et al. Tenecteplase for ischemic stroke at 4.5 to 24 hours without thrombectomy[J]. N Engl J Med，2024，391（3）：203-212.
[17] LEE V H. Small step or giant leap？Expanding the acute stroke thrombolysis window to 24 hours[J]. N Engl J Med，2024，391（3）：273-275.
[18] RAJA S，ALI A，QAMMAR A，et al. Reteplase versus alteplase for acute ischemic stroke：a systematic review and meta-analysis[J/OL]. Am J Ther，2024[2024-12-18]. https://doi.org/10.1097/mjt.0000000000001823.
[19] MARTIN U，KAUFMANN B，NEUGEBAUER G. Current clinical use of reteplase for thrombolysis. A pharmacokinetic-pharmacodynamic perspective[J]. Clin Pharmacokinet，1999，36（4）：265-276.
[20] SMALLING R W，BODE C，KALBFLEISCH J，et al. More rapid，complete，and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction[J]. Circulation，1995，91（11）：2725-2732.
[21] BODE C，SMALLING R W，BERG G，et al. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase（recombinant plasminogen activator）and front-loaded，accelerated alteplase（recombinant tissue plasminogen activator）in patients with acute myocardial infarction[J]. Circulation，1996，94（5）：891-898.
[22] PANNELL R，GUREWICH V. Pro-urokinase：a study of its stability in plasma and of a mechanism for its selective fibrinolytic effect[J]. Blood，1986，67（5）：1215-1223.
[23] GUREWICH V. Pro-urokinase：physiochemical properties and promotion of its fibrinolytic activity by urokinase and by tissue plasminogen activator with which it has a complementary mechanism of action[J]. Semin Thromb Hemost，1988，14（1）：110-115.
[24] LI S Y，GU H Q，LI H，et al. Reteplase versus alteplase for acute ischemic stroke[J]. N Engl J Med，2024，390（24）：2264-2273.
[25] AKHTAR M，KARIM H. Reteplase：a promising alternative in acute ischemic stroke management[J/OL]. Neurosurg Rev，2024，47（1）：379[2024-12-18]. https://doi.org/10.1007/s10143-024-02642-3.
[26] LI S Y，GU H Q，FENG B Y，et al. Safety and efficacy of intravenous recombinant human prourokinase for acute ischaemic stroke within 4.5 h after stroke onset（PROST-2）：a phase 3，open-label，non-inferiority，randomised controlled trial[J]. Lancet Neurol，2025，24（1）：33-41.
[27] TURC G，NGUYEN T N. Reconsidering prourokinase for acute ischaemic stroke[J]. Lancet Neurol，2025，24（1）：2-3.
[28] KHATRI P，KLEINDORFER D O，DEVLIN T，et al. Effect of alteplase vs. aspirin on functional outcome for patients with acute ischemic stroke and minor nondisabling neurologic deficits：the PRISMS randomized clinical trial[J]. JAMA，2018，320（2）：156-166.
[29] CHEN H S，CUI Y，ZHOU Z H，et al. Dual antiplatelet therapy vs. alteplase for patients with minor nondisabling acute ischemic stroke：the ARAMIS randomized clinical[J]. JAMA，2023，329（24）：2135-2144.
[30] COUTTS S B，DUBUC V，MANDZIA J，et al. Tenecteplase-tissue-type plasminogen activator evaluation for minor ischemic stroke with proven occlusion[J]. Stroke，2015，46（3）：769-774.
[31] COUTTS S B，ANKOLEKAR S，APPIREDDY R，et al. Tenecteplase versus standard of care for minor ischaemic stroke with proven occlusion（TEMPO-2）：a randomised，open label，phase 3 superiority trial[J]. Lancet，2024，403（10444）：2597-2605.
[32] SACCO S，TURC G. Advances and challenges in the acute treatment of minor ischaemic stroke[J]. Lancet，2024，403（10444）：2566-2568.
[33] YOSHIMURA S，SAKAI N，YAMAGAMI H，et al. Endovascular therapy for acute stroke with a large ischemic region[J]. N Engl J Med，2022，386（14）：1303-1313.
[34] HUO X C，MA G T，TONG X，et al. Trial of endovascular therapy for acute ischemic stroke with large infarct[J]. N Engl J Med，2023，388（14）：1272-1283.
[35] SARRAJ A，HASSAN A E，ABRAHAM M G，et al. Trial of endovascular thrombectomy for large ischemic strokes[J]. N Engl J Med，2023，388（14）：1259-1271.
[36] BENDSZUS M，FIEHLER J，SUBTIL F，et al. Endovascular thrombectomy for acute ischaemic stroke with established large infarct：multicentre，open-label，randomised trial[J]. Lancet，2023，402（10414）：1753-1763.
[37] COSTALAT V，JOVIN T G，ALBUCHER J F，et al. Trial of thrombectomy for stroke with a large infarct of unrestricted size[J]. N Engl J Med，2024，390（18）：167716-167789.
[38] YOO A J，ZAIDAT O O，SHETH S A，et al. Thrombectomy for stroke with large infarct on noncontrast CT：the TESLA randomized clinical trial[J]. JAMA，2024，332（16）：1355-1366.
[39] SARRAJ A，ABRAHAM M G，HASSAN A E，et al. Endovascular thrombectomy plus medical care versus medical care alone for large ischaemic stroke：1-year outcomes of the SELECT2 trial[J]. Lancet，2024，403（10428）：731-740.
[40] CHEN H W，LEE J S，MICHEL P，et al. Endovascular stroke thrombectomy for patients with large ischemic core：a review[J]. JAMA Neurol，2024，81（10）：1085-1093.
[41] GUTIERREZ J，TURAN T N，HOH B L，et al. Intracranial atherosclerotic stenosis：risk factors，diagnosis and treatment[J]. Lancet Neurol，2022，21（4）：355-368.
[42] WANG Y J，ZHAO X Q，LIU L P，et al. Prevalence and outcomes of symptomatic intracranial large artery stenoses and occlusions in China：the Chinese intracranial atherosclerosis（CICAS）study[J]. Stroke，2014，45（3）：663-669.
[43] CHIMOWITZ M I，LYNN M J，DERDEYN C P，et al. Stenting versus aggressive medical therapy for intracranial arterial stenosis[J]. N Engl J Med，2011，365（11）：993-1003.
[44] ZAIDAT O O，FITZSIMMONS B F，WOODWARD B K，et al. Effect of a balloon-expandable intracranial stent vs. medical therapy on risk of stroke in patients with symptomatic intracranial stenosis：the VISSIT randomized clinical trial[J]. JAMA，2015，313（12）：1240-1248.
[45] GAO P，WANG T，WANG D M，et al. Effect of stenting plus medical therapy vs. medical therapy alone on risk of stroke and death in patients with symptomatic intracranial stenosis：the CASSISS randomized clinical trial[J]. JAMA，2022，328（6）：534-542.
[46] SUN X，DENG Y M，ZHANG Y，et al. Balloon angioplasty vs. medical management for intracranial artery stenosis：the BASIS randomized clinical trial[J]. JAMA，2024，332（13）：1059-1069.
[47] MORRIS N A，SIMARD J M，CHATURVEDI S. Surgical management for primary intracerebral hemorrhage[J/OL]. Neurology，2024，103（4）：e209714[2024-12-18]. https://doi.org/10.1212/wnl.0000000000209714.
[48] LI Q，YAKHKIND A，ALEXANDROV A W，et al. Code ICH：a call to action[J]. Stroke，2024，55（2）：494-505.
[49] LEASURE A C，SHETH K N，COMEAU M，et al. Identification and validation of hematoma volume cutoffs in spontaneous，supratentorial deep intracerebral hemorrhage[J]. Stroke，2019，50（8）：2044-2049.
[50] SONDAG L，SCHREUDER F，BOOGAARTS H D，et al. Neurosurgical intervention for supratentorial intracerebral hemorrhage[J]. Ann Neurol，2020，88（2）：239-250.
[51] HANLEY D F，THOMPSON R E，ROSENBLUM M，et al. Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation（MISTIE Ⅲ）：a randomised，controlled，open-label，blinded endpoint phase 3 trial[J]. Lancet，2019，393（10175）：1021-1032.
[52] MENDELOW A D，GREGSON B A，FERNANDES H M，et al. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the international surgical trial in intracerebral haemorrhage（STICH）：a randomised trial[J]. Lancet，2005，365（9457）：387-397.
[53] MENDELOW A D，GREGSON B A，ROWAN E N，et al. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial lobar intracerebral haematomas（STICH Ⅱ）：a randomised trial[J]. Lancet，2013，382（9890）：397-408.
[54] PRADILLA G，RATCLIFF J J，HALL A J，et al. Trial of early minimally invasive removal of intracerebral hemorrhage[J]. N Engl J Med，2024，390（14）：1277-1289.
[55] SEIFFGE D J，ANDERSON C S. Treatment for intracerebral hemorrhage：dawn of a new era[J]. Int J Stroke，2024，19（5）：482-489.
[56] SEIFFGE D J，FANDLER-HOFLER S，DU Y，et al. Intracerebral haemorrhage—mechanisms，diagnosis and prospects for treatment and prevention[J]. Nat Rev Neurol，2024，20（12）：708-723.
[57] BECK J，FUNG C，STRBIAN D，et al. Decompressive craniectomy plus best medical treatment versus best medical treatment alone for spontaneous severe deep supratentorial intracerebral haemorrhage：a randomised controlled clinical trial[J]. Lancet，2024，403（10442）：2395-2404.
[58] KLIJN C J，DAMMERS R，SPRIGG N. Decompressive craniectomy for deep intracerebral haemorrhage：a SWITCH towards better outcomes？[J]. Lancet，2024，403（10442）：2351-2353.
[59] KAN P，MARAGKOS G A，SRIVATSAN A，et al. Middle meningeal artery embolization for chronic subdural hematoma：a multi-center experience of 154 consecutive embolizations[J]. Neurosurgery，2021，88（2）：268-277.
[60] FIORELLA D，ARTHUR A S. Middle meningeal artery embolization for the management of chronic subdural hematoma[J]. J Neurointerv Surg，2019，11（9）：912-915.
[61] IRONSIDE N，NGUYEN C，DO Q，et al. Middle meningeal artery embolization for chronic subdural hematoma：a systematic review and meta-analysis[J]. J NeuroInterv Surg，2021，13（10）：951-957.
[62] SCHMOLLING A H，PEREZ-GARCIA C，TREJO C，et al. Middle meningeal artery embolization for management of chronic subdural hematoma[J/OL]. Radiographics，2024，44（4）：e230158[2024-12-18]. https://doi.org/10.1148/rg.230158.
[63] KHORASANIZADEH M，MAROUFI S F，MUKHERJEE R，et al. Middle meningeal artery embolization in adjunction to surgical evacuation for treatment of subdural hematomas：a nationwide comparison of outcomes with isolated surgical evacuation[J]. Neurosurgery，2023，93（5）：1082-1089.
[64] ADUSUMILLI G，GHOZY S，KALLMES K M，et al. Common data elements reported on middle meningeal artery embolization in chronic subdural hematoma：an interactive systematic review of recent trials[J]. J Neurointerv Surg，2022，14（10）：1027-1032.
[65] LIU J M，NI W，ZUO Q，et al. Middle meningeal artery embolization for nonacute subdural hematoma[J]. N Engl J Med，2024，391（20）：1901-1912.
[66] FIORELLA D，MONTEITH S J，HANEL R，et al. Embolization of the middle meningeal artery for chronic subdural hematoma[J/OL]. N Engl J Med，2024[2024-12-18]. https://doi.org/10.1056/nejmoa2409845.
[67] DAVIES J M，KNOPMAN J，MOKIN M，et al. Adjunctive middle meningeal artery embolization for subdural hematoma[J]. N Engl J Med，2024，391（20）：1890-1900.
[68] KAN P. Middle meningeal artery embolization and nonacute subdural hematoma[J/OL]. N Engl J Med，2024：2410915[2024-12-25]. https://doi.org/10.1056/nejme2410915.
[69] KAPTOGE S，DI ANGELANTONIO E，LOWE G，et al. C-reactive protein concentration and risk of coronary heart disease，stroke，and mortality：an individual participant meta-analysis[J]. Lancet，2010，375（9709）：132-140.
[70] KELLY P J，LEMMENS R，TSIVGOULIS G. Inflammation and stroke risk：a new target for prevention[J]. Stroke，2021，52（8）：2697-2706.
[71] NIDORF S M，FIOLET A T L，MOSTERD A，et al. Colchicine in patients with chronic coronary disease[J]. N Engl J Med，2020，383（19）：1838-1847.
[72] TARDIF J C，KOUZ S，WATERS D D，et al. Efficacy and safety of low-dose colchicine after myocardial infarction[J]. N Engl J Med，2019，381（26）：2497-2505.
[73] LI J J，MENG X，SHI F D，et al. Colchicine in patients with acute ischaemic stroke or transient ischaemic attack（CHANCE-3）：multicentre，double blind，randomised，placebo controlled trial[J/OL]. BMJ，2024，385：e079061[2024-12-20]. https://doi.org/10.1136/bmj-2023-079061.
[74] KELLY P，LEMMENS R，WEIMAR C，et al. Long-term colchicine for the prevention of vascular recurrent events in non-cardioembolic stroke（CONVINCE）：a randomised controlled trial[J]. Lance，2024，404（10448）：125-133.
[75] WOLF P A，ABBOTT R D，KANNEL W B. Atrial fibrillation as an independent risk factor for stroke：the Framingham study[J]. Stroke，1991，22（8）：983-988.
[76] SEIFFGE D J，CANCELLONI V，RÄBER L，et al. Secondary stroke prevention in people with atrial fibrillation：treatments and trials[J]. Lancet Neurol，2024，23（4）：404-417.
[77] CONNOLLY S J，EIKELBOOM J，JOYNER C，et al. Apixaban in patients with atrial fibrillation[J]. N Engl J Med，2011，364（9）：806-817.
[78] RUFF C T，GIUGLIANO R P，BRAUNWALD E，et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation：a meta-analysis of randomised trials[J]. Lancet，2014，383（9921）：955-962.
[79] WERRING D J，DEHBI H M，AHMED N，et al. Optimal timing of anticoagulation after acute ischaemic stroke with atrial fibrillation（OPTIMAS）：a multicentre，blinded-endpoint，phase 4，randomised controlled trial[J/OL]. Lancet，2024：S0140-6736（24）02197-4[2024-12-18]. https://doi.org/10.1016//S0140-6736（24）02197-4.
[80] MARKUS H S. When to start of anticoagulation after stroke and alternative thrombolytic agents：highlights at world stroke congress 2024[J]. Int J Stroke，2024，19（10）：1080-1082.
[81] SANDSET E C，DE SOUSA D A. Optimal anticoagulation timing after ischaemic stroke in patients with atrial fibrillation[J/OL]. Lancet，2024：S0140-6736（24）02259-1[2024-12-18]. https://doi.org/10.1016/s0140-6736（24）02259-1.
[82] KAMEL H，LONGSTRETH W T，TIRSCHWELL D L，et al. Apixaban to prevent recurrence after cryptogenic stroke in patients with atrial cardiopathy：the ARCADIA randomized clinical trial[J]. JAMA，2024，331（7）：573-581.
[83] QURESHI Z，ALTAF F，JAMIL A，et al. Breaking boundaries：exploring recent advances in anticoagulation and thrombosis management：a comprehensive review[J]. Ann Med Surg（Lond），2024，86（11）：6585-6597.
[84] CAMPORA A，LISI M，PASTORE M C，et al. Atrial fibrillation，atrial myopathy，and thromboembolism：the additive value of echocardiography and possible new horizons for risk stratification[J/OL]. J Clin Med，2024，13（13）：3921[2024-12-18]. https://doi.org/10.3390/jcm13133921.
[85] HEALEY J S，CONNOLLY S J，GOLD M R，et al. Subclinical atrial fibrillation and the risk of stroke[J]. N Engl J Med，2012，366（2）：120-129.
[86] GLOTZER T V，HELLKAMP A S，ZIMMERMAN J，et al. Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke：report of the atrial diagnostics ancillary study of the mode selection trial（MOST）[J]. Circulation，2003，107（12）：1614-1619.
[87] HEALEY J S，LOPES R D，GRANGER C B，et al. Apixaban for stroke prevention in subclinical atrial fibrillation[J]. N Engl J Med，2024，390（2）：107-117.
[88] SVENNBERG E. What lies beneath the surface—treatment of subclinical atrial fibrillation[J]. N Engl J Med，2024，390（2）：175-177.